Latest news with #Aetion
Business Wire
11-07-2025
- Business
- Business Wire
Datavant Completes Acquisition of Aetion
NEW YORK--(BUSINESS WIRE)-- Datavant, a leading health data platform company, today announced the successful completion of its acquisition of Aetion, a leading real-world evidence (RWE) platform that powers critical decision-making in healthcare. Aetion is now part of Datavant's Life Sciences business. We will leverage our complementary capabilities to help create a bridge between different datasets and transform the way data is being leveraged across the drug development continuum. "This transaction represents the beginning of a promising new chapter together for two industry-leaders whose joint mission is to make real world evidence truly actionable, and we are delighted to welcome the Aetion team to Datavant,' said Kyle Armbrester, CEO of Datavant. With the completion of this acquisition, Datavant is well-positioned to deliver an end-to-end platform for data feasibility and analysis, enabling healthcare and life sciences companies to more efficiently answer research questions about the clinical impact of therapies in development and in market. 'We will leverage our complementary capabilities to help create a bridge between different datasets and transform the way data is being leveraged across the drug development continuum,' Armbrester added. Datavant and Aetion have a combined ecosystem of over 300 data partners comprising datasets and insights across electronic health records, claims, specialty pharmacy, registries, imaging, lab, social determinants of health, and more. About Datavant Datavant is a health data platform company. We make the world's health data secure, accessible, and actionable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 80,000 hospitals and clinics, 75% of the 100 largest health systems, and an ecosystem of 300+ real-world data partners. To learn more about Datavant, visit and follow us on LinkedIn. About Aetion Aetion®, a Datavant company, is a global healthcare technology company that delivers real-world evidence (RWE) solutions to biopharmaceutical companies, medical device manufacturers, payers, and regulators. Powered by Aetion Evidence Platform®, Aetion applies advanced causal inference, rigorous epidemiologic methods, and purpose-built AI to transform complex healthcare data into transparent, reliable evidence on the safety, effectiveness, and value of medical treatments. Through this evidence-based approach, Aetion informs healthcare's most critical decisions—what works best, for whom, and when—while enabling scalable solutions for regulatory submissions, market access, and clinical development. Aetion's investors include Flare Capital Partners, NEA, Warburg Pincus, B Capital, and leading life sciences and payer organizations. Learn more at and follow us on LinkedIn.
Business Wire
15-05-2025
- Business
- Business Wire
Datavant to Acquire Aetion, Empowering Healthcare and Life Sciences Organizations to Generate High-Quality, Scalable Real-World Evidence from Connected, Privacy-Protected Data
NEW YORK--(BUSINESS WIRE)--Datavant, a leading health data platform company, today announced that it has signed an agreement to acquire Aetion, a leading real-world evidence (RWE) platform that powers critical decision-making in healthcare. With this acquisition, Aetion will join Datavant to deliver an end-to-end RWE platform, enabling healthcare and life sciences companies to more efficiently answer research questions about the clinical impact of therapies in development and in market. The companies will focus on leveraging their complementary capabilities to create an end-to-end offering on data discovery, linkage, privacy, curation and advanced analysis to enable their life sciences customers to create analytics-ready insights. Share This complementary combination unites two leaders to make RWE truly actionable, covering the full spectrum of services needed to deliver scientifically validated, transparent and reproducible RWE accepted by global regulators, including the FDA and EMA. Aetion brings industry-leading technology, services and data partners to help life science and medical device customers develop decision-grade evidence plans and analyses. Stakeholders across the healthcare value chain use Datavant's industry-standard platform for secure, compliant health data exchange to fuel connected, comprehensive insights that empower smarter decisions and advance patient outcomes. 'As Datavant has grown and scaled, our life sciences and ecosystem partners have been asking us for a deeper capability set to bring together disparate data sources so they can tap into a more comprehensive and longitudinal view of patient health across the product lifecycle," said Kyle Armbrester, Chief Executive Officer, Datavant. 'The addition of Aetion's team of scientists and technologists further bolsters our complementary capabilities and expertise so we can better leverage data from our ecosystem of partners to support efforts before, during, and after commercialization - generating evidence from trial to treatment and beyond to deliver life-improving therapies.' The companies will focus on leveraging their complementary capabilities to create an end-to-end offering on data discovery, linkage, privacy, curation and advanced analysis to enable their ecosystem and life sciences partners to create analytics-ready insights. This announcement follows the launch of Datavant Connect powered by AWS Clean Rooms, an enhanced capability that facilitates cloud-first data discovery and evaluation to accelerate time to insight. Through Datavant Connect, ecosystem partners' data is more easily and equitably accessible and able to be combined with complementary data sources, thus unlocking additional value to partners and customers alike. Aetion greatly enhances the Datavant Connect platform's data discovery features, and will enhance privacy assessments and give end-customers clean datasets and analytics they can leverage for a range of uses. In addition, the Aetion Evidence Platform is now available in AWS Marketplace. This announcement also coincides with the launch of Aetion® Activate. Activate expands Aetion's software portfolio to better serve biostatisticians and data scientists, creating a collaborative, auditable, and secure platform for both code and no-code users. It also removes the burdens of manual, error-prone data preparation—freeing teams to focus on research and critical analysis. Together with Datavant's connectivity and tokenization capabilities, Aetion now offers a more integrated ecosystem for preparing and analyzing real-world data at scale. 'Our mission at Aetion has always been to power critical decisions in healthcare with data science-driven technology,' said Jeremy Rassen, ScD, CEO of Aetion. 'By joining forces with Datavant, we'll unlock the full potential of real-world evidence to advance confident, data-driven decisions that improve patient care. Today, we are taking a bold step toward realizing our shared vision: a world where health data is seamlessly connected and actionable—so we can answer what treatments work, for whom, and what they should cost.' Upon closing, Datavant and Aetion will have a combined ecosystem of over 300 data partners. Datavant's RWD partners comprise datasets across electronic health records, claims, specialty pharmacy, registries, imaging, lab, social determinants of health, and more. With Aetion, RWD partners across the Datavant ecosystem will gain improved visibility of their data's utility through sharper querying of the datasets, scaling value, demand, and additional use cases across a more expansive base of life sciences companies. About Datavant Datavant is a health data platform company. We make the world's health data secure, accessible, and actionable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 70,000 hospitals and clinics, 75% of the 100 largest health systems, and an ecosystem of 300+ real-world data partners. To learn more about Datavant, visit and follow us on LinkedIn. About Aetion Aetion® is a global healthcare technology company that delivers real-world evidence (RWE) solutions to biopharmaceutical companies, medical device manufacturers, payers, and regulators. Powered by Aetion Evidence Platform®, Aetion applies advanced causal inference, rigorous epidemiologic methods, and purpose-built AI to transform complex healthcare data into transparent, reliable evidence on the safety, effectiveness, and value of medical treatments. Through this evidence-based approach, Aetion informs healthcare's most critical decisions—what works best, for whom, and when—while enabling scalable solutions for regulatory submissions, market access, and clinical development. Aetion's investors include Flare Capital Partners, NEA, Warburg Pincus, B Capital, and leading life sciences and payer organizations. Learn more at and follow us on LinkedIn.
Yahoo
15-05-2025
- Business
- Yahoo
Datavant to Acquire Aetion, Empowering Healthcare and Life Sciences Organizations to Generate High-Quality, Scalable Real-World Evidence from Connected, Privacy-Protected Data
Combination will enable faster, more actionable insights across the clinical and commercial lifecycle NEW YORK, May 15, 2025--(BUSINESS WIRE)--Datavant, a leading health data platform company, today announced that it has signed an agreement to acquire Aetion, a leading real-world evidence (RWE) platform that powers critical decision-making in healthcare. With this acquisition, Aetion will join Datavant to deliver an end-to-end RWE platform, enabling healthcare and life sciences companies to more efficiently answer research questions about the clinical impact of therapies in development and in market. This complementary combination unites two leaders to make RWE truly actionable, covering the full spectrum of services needed to deliver scientifically validated, transparent and reproducible RWE accepted by global regulators, including the FDA and EMA. Aetion brings industry-leading technology, services and data partners to help life science and medical device customers develop decision-grade evidence plans and analyses. Stakeholders across the healthcare value chain use Datavant's industry-standard platform for secure, compliant health data exchange to fuel connected, comprehensive insights that empower smarter decisions and advance patient outcomes. "As Datavant has grown and scaled, our life sciences and ecosystem partners have been asking us for a deeper capability set to bring together disparate data sources so they can tap into a more comprehensive and longitudinal view of patient health across the product lifecycle," said Kyle Armbrester, Chief Executive Officer, Datavant. "The addition of Aetion's team of scientists and technologists further bolsters our complementary capabilities and expertise so we can better leverage data from our ecosystem of partners to support efforts before, during, and after commercialization - generating evidence from trial to treatment and beyond to deliver life-improving therapies." The companies will focus on leveraging their complementary capabilities to create an end-to-end offering on data discovery, linkage, privacy, curation and advanced analysis to enable their ecosystem and life sciences partners to create analytics-ready insights. This announcement follows the launch of Datavant Connect powered by AWS Clean Rooms, an enhanced capability that facilitates cloud-first data discovery and evaluation to accelerate time to insight. Through Datavant Connect, ecosystem partners' data is more easily and equitably accessible and able to be combined with complementary data sources, thus unlocking additional value to partners and customers alike. Aetion greatly enhances the Datavant Connect platform's data discovery features, and will enhance privacy assessments and give end-customers clean datasets and analytics they can leverage for a range of uses. In addition, the Aetion Evidence Platform is now available in AWS Marketplace. This announcement also coincides with the launch of Aetion® Activate. Activate expands Aetion's software portfolio to better serve biostatisticians and data scientists, creating a collaborative, auditable, and secure platform for both code and no-code users. It also removes the burdens of manual, error-prone data preparation—freeing teams to focus on research and critical analysis. Together with Datavant's connectivity and tokenization capabilities, Aetion now offers a more integrated ecosystem for preparing and analyzing real-world data at scale. "Our mission at Aetion has always been to power critical decisions in healthcare with data science-driven technology," said Jeremy Rassen, ScD, CEO of Aetion. "By joining forces with Datavant, we'll unlock the full potential of real-world evidence to advance confident, data-driven decisions that improve patient care. Today, we are taking a bold step toward realizing our shared vision: a world where health data is seamlessly connected and actionable—so we can answer what treatments work, for whom, and what they should cost." Upon closing, Datavant and Aetion will have a combined ecosystem of over 300 data partners. Datavant's RWD partners comprise datasets across electronic health records, claims, specialty pharmacy, registries, imaging, lab, social determinants of health, and more. With Aetion, RWD partners across the Datavant ecosystem will gain improved visibility of their data's utility through sharper querying of the datasets, scaling value, demand, and additional use cases across a more expansive base of life sciences companies. About Datavant Datavant is a health data platform company. We make the world's health data secure, accessible, and actionable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousands of organizations, more than 70,000 hospitals and clinics, 75% of the 100 largest health systems, and an ecosystem of 300+ real-world data partners. To learn more about Datavant, visit and follow us on LinkedIn. About Aetion Aetion® is a global healthcare technology company that delivers real-world evidence (RWE) solutions to biopharmaceutical companies, medical device manufacturers, payers, and regulators. Powered by Aetion Evidence Platform®, Aetion applies advanced causal inference, rigorous epidemiologic methods, and purpose-built AI to transform complex healthcare data into transparent, reliable evidence on the safety, effectiveness, and value of medical treatments. Through this evidence-based approach, Aetion informs healthcare's most critical decisions—what works best, for whom, and when—while enabling scalable solutions for regulatory submissions, market access, and clinical development. Aetion's investors include Flare Capital Partners, NEA, Warburg Pincus, B Capital, and leading life sciences and payer organizations. Learn more at and follow us on LinkedIn. View source version on Contacts Media Contact Lynn ShepherdHead of Corporate Communications, Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-04-2025
- Business
- Yahoo
Define Ventures Appoints Carolyn Magill as Venture Partner
The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies. Carolyn is a seasoned healthcare executive and two-time CEO, having held executive leadership positions across multiple corners of the ecosystem. Prior to joining Define, Carolyn was CEO of Aetion, whose platform transforms real-world data into regulatory-grade evidence for critical healthcare decisions. She also previously served as CEO of Remedy Partners, the premier bundled payments software and services company, and as Executive Vice President of Payer Strategy and Operations at Evolent Health, where she helped drive the company's progression from startup through IPO. She also held several leadership roles at UnitedHealth Group, including Chief Operating Officer of its Community and State plan in New Jersey. "Carolyn's extensive experience across payer, provider, and pharmaceutical sectors makes her uniquely qualified to guide the next generation of health tech innovators," said Lynne Chou O'Keefe, founder and managing partner at Define Ventures. "Having had the privilege of partnering with Carolyn as an advisor for many years, we're confident her deep expertise, particularly in data and AI applications within the pharmaceutical landscape, will be invaluable to our partner companies." "Define represents the best of venture — an incredible founder community and a team of experienced operators who truly understand what it takes to build in healthcare," said Magill. "Throughout my career, I've worked across many corners of healthcare, and joining Define allows me to bring that experience to the earliest stages of innovation, helping founders turn ideas into impact." Carolyn's appointment complements Define Ventures' existing venture partners, Bruce Broussard, former CEO of Humana, and Frank Williams, co-founder and former CEO of Evolent Health, creating a powerful trio of industry leaders with comprehensive experience across payer, provider and pharmaceutical sectors. Together, they bring unparalleled strategic depth to Define's partner companies. Define Ventures has $800 million in assets under management and partners with companies at the seed, series A and series B stages. The firm impacts leading health tech entrepreneurs with its high conviction approach, partnering with over two dozen companies including Hims & Hers (NYSE: HIMS), Unite Us and Cohere learn more about Define Ventures, visit About Define Ventures Define Ventures is one of the largest funds focused on early-stage health tech companies. With $800 million AUM, we take a high conviction approach in partnering with companies in the earliest stages. We believe the future of healthcare will be defined by those who bring together a deep understanding of the healthcare ecosystem paired with a technology-driven mindset. Our team was built to this vision, bringing together founders and investors who built category-defining companies and delivered over $25 billion in exit value, including Livongo (NYSE: LVGO), Evolent (NYSE: EVH), and Hims & Hers (NYSE: HIMS). View original content to download multimedia: SOURCE Define Ventures
